SCHEMBL21783689

SCHEMBL21783689

COCCn1ncc2cccc(N)c21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.38
ALDH1A1 P00352 4/20 0.38
TDP1 Q9NUW8 2/20 0.38
LMNA P02545 2/20 0.38
MPO P05164 1/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
MITF O75030 1/20 0.36
PKM P14618 1/20 0.36
MAOB P27338 2/20 0.36
MAOA P21397 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
PDE10A Q9Y233 1/20 0.34
ALOX15 P16050 1/20 0.34
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ADRA2A P08913 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28329487 0.82 ADRA2A (0.48) MAPK1MPONPC1RAB9AMITF
SCHEMBL27199681 0.79 HSD17B10 (0.42) MAPK1ALDH1A1TDP1LMNAMPO
SCHEMBL25832867 0.79 CASR (0.43) MAPK1ALDH1A1LMNAMPONPC1
SCHEMBL7571970 0.79 HASPIN (0.47) MAPK1LMNAHTR2AHTR2CADRA2A
SCHEMBL30848002 0.79 HASPIN (0.47) MAPK1LMNAHTR2AHTR2CADRA2A
SCHEMBL3349561 0.76 MPO (0.39) ALDH1A1TDP1LMNAMPOMAOB
SCHEMBL30304731 0.74 DGAT1 (0.35) NPC1HTR2AHTR2CADRA2A
SCHEMBL5946299 0.74 CYP1A2 (0.57) MPONPC1RAB9AMITFPKM
SCHEMBL4955235 0.74 MCHR1 (0.36) ALDH1A1TDP1LMNANPC1RAB9A
SCHEMBL3364159 0.73 ADORA3 (0.38) ALDH1A1LMNANPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4577536-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY Hotspot Therapeutics, Inc. (US) 2025-07-02 EP disclosed
US-20240150321-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. 2024-05-09 US disclosed
US-20240150365-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. 2024-05-09 US disclosed
WO-2024044344-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 WO disclosed
WO-2024044344-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 WO disclosed
WO-2024044730-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 WO disclosed
WO-2024044730-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 WO disclosed
WO-2020047208-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. (US) 2020-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150321-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL3 MAPK1 564/4885ALDH1A1 3268/4885TDP1 878/4885
US-20240150365-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL6B MAPK1 375/4885ALDH1A1 3059/4885TDP1 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.